Bio-Rad Reports 2 Percent Lift in Q2 Sales | GenomeWeb

NEW YORK (GenomeWeb) — Bio-Rad reported after the close of the market on Tuesday a 2 percent increase in second quarter revenues despite essentially flat sales for its Life Science segment.

For the quarter ended June 30, the Hercules, Calif.-based firm reported revenues of $536.8 million compared to $525.3 million in Q2 2013 and falling short of the consensus analyst estimate of $537.6 million.

On a currency-neutral basis, quarterly revenues increased 1 percent year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.